Evidence map›Paper›PMID 42393313›Full record

ArticleExperimental & molecular medicine2026

ISGylation-mediated stabilization of CYP4Z1 fuels breast cancer initiation and progression.

Yin Yuan, Yu Lu, Xuedan Han, Yidong Zhang, Qianqian Guo, Hong Yao, Qiyi Yu, Manzhen Zhou, Xinting Huang, Hongqi Wang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yin Yuan *School of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China.
Yu Lu *School of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China.
Xuedan HanSchool of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China.
Yidong ZhangDepartment of Biological Sciences, Virginia Tech, Blacksburg, VA, USA.
Qianqian GuoDepartment of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, P. R. China.
Hong YaoSchool of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China.ORCID http://orcid.org/0000-0002-9594-9598
Qiyi YuMellon College of Science, Carnegie Mellon University, Pittsburgh, PA, USA.
Manzhen ZhouSchool of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China.
Xinting HuangSchool of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China.
Hongqi WangSchool of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China.
Miaomiao NiuSchool of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China.
Jun YinSchool of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China.
Haibo RongJiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Lei HuangDepartment of Molecular Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, 01605, USA. lei.huang@umassmed.edu.
Xiaoman LiJiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, China. lixm@njucm.edu.cn.
Shengtao XuSchool of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China. cpuxst@cpu.edu.cn.
Lufeng ZhengSchool of Life Science and Technology, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, China. zhlf@cpu.edu.cn.ORCID http://orcid.org/0000-0002-2183-4974

Funding

China Postdoctoral Science Foundation 2023M731453, 2024T170367
6 · The paper itself

Abstract

Tumor-initiating cells (TICs) are central to cancer progression and metastasis; however, they remain challenging to target therapeutically. Here, using a breast-specific CYP4Z1-transgenic MMTV-PyMT mouse model, we show that CYP4Z1 notably accelerates tumor initiation, enlarges tumor size, promotes metastasis, and expands TIC populations. Multi-omics analyses reveal that CYP4Z1

Indexed as

Breast NeoplasmsCytochrome P450 Family 4CytokinesUbiquitinsAnimalsCell Line, TumorDisease ProgressionFemaleHumansMiceUbiquitinationCYP4Z1 protein, humanCytochrome P450 Family 4CytokinesUbiquitins

Identifiers

PMID42393313
PMCPMC13434766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.